Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surpass discontinued

This article was originally published in The Tan Sheet

Executive Summary

Wrigley Healthcare Division will be dissolved after discontinuing sales of its Surpass antacid chewing gum March 28. "Despite its quality, Surpass...has not been able to build broad enough popularity with consumers needed to support a brand long-term," 1Wrigley's Web site notes. Healthcare division, which was created two years ago to support Surpass' launch, will be phased out by May, firm says, with employees rejoining parent company. Wrigley's R&D team will "continue to explore the delivery of functional benefits" through chewing gum, with a focus on indications such as throat and cough relief, dental benefits. Firm has attributed poor Surpass sales to difficulty in convincing consumers to switch from liquid/pill antacid forms to gum (2"The Tan Sheet" March 4, 2002, p. 6)...

You may also be interested in...



Surpass Antacid Gum Marketing Strategy Shift Planned By Wrigley

Wrigley Healthcare is modifying its marketing strategy for Surpass antacid gum to increase consumer trials of the product after its introduction resulted in lower than expected sales

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel